Dr. Daelyn Y. Richards MD, PhD
Resident Physician
University of Colorado
Daelyn Y. Richards, MD, PhD, is a combined Pediatrics and Medical Genetics resident at the University of Colorado and Children’s Hospital Colorado whose work sits at the intersection of clinical genetics, artificial intelligence, and clinical informatics. Her scholarly interests include longitudinal phenotyping of inherited metabolic disorders, precision medicine, genomic data science, and translating data-driven insights into personalized clinical workflows.
Dr. Richards is actively involved in the clinical AI and informatics communities through the American Medical Informatics Association and the University of Toronto’s T-CAIREM, and has completed advanced training through the American Board of Artificial Intelligence in Medicine. She is also pursuing advanced Epic Cosmos training to develop computational approaches to studying rare metabolic disease at scale.
Her broader interests center on how AI can augment—not replace—physician expertise, how medical education should evolve as AI capabilities expand, and how health systems can responsibly translate emerging technologies into clinical practice. She ultimately hopes to bridge medicine, technology, and health-system leadership while improving care for patients with rare genetic and metabolic disorders.
Dr. Richards is actively involved in the clinical AI and informatics communities through the American Medical Informatics Association and the University of Toronto’s T-CAIREM, and has completed advanced training through the American Board of Artificial Intelligence in Medicine. She is also pursuing advanced Epic Cosmos training to develop computational approaches to studying rare metabolic disease at scale.
Her broader interests center on how AI can augment—not replace—physician expertise, how medical education should evolve as AI capabilities expand, and how health systems can responsibly translate emerging technologies into clinical practice. She ultimately hopes to bridge medicine, technology, and health-system leadership while improving care for patients with rare genetic and metabolic disorders.
